A Mayo Clinic study of more than 4,600 patients redraws the map of the most common chronic liver disease.

Citi upgraded Arcturus to ‘Buy’ and raised the price target to $20 from $8, according to The Fly.

A new indication for an existing drug has been approved in Japan to treat patients with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2, a group of rare genetic liver disorders.

Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease in children and adolescents, closely mirroring the global rise in childhood obesity.

If scientists could shrink themselves to microscopic size and take a journey through the human body—like the submarine crew in the 1966 science fiction classic "Fantastic Voyage"—one of their first ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis before age 50 years is associated with both genetic and metabolic factors, according ...

The project team led by Professor Zheng Zongli (right) of CityUHK’s Department of Biomedical Sciences, will focus on liver and cardiovascular genetic diseases, harnessing state-of-the-art “DNA surgery ...

Patients faced with the diagnosis of a life-threatening liver disease have to consider the seriousness of having a liver transplant, which can be a definitive cure for many acquired and genetic liver ...

A new review published in the International Journal of Obesity is sounding the alarm about one of the fastest-growing liver ...